Effekt og sikkerhed af Depemokimab sammenlignet med Mepolizumab hos voksne med recidiverende eller refraktær eosinofil granulomatose med polyangiitis (EGPA) (OCEAN)
En 52-ugers, randomiseret, dobbeltblind, dobbelt-dummy, parallelgruppe, multicenter, non-inferioritetsundersøgelse for at undersøge effektiviteten og sikkerheden af Depemokimab sammenlignet med Mepolizumab hos voksne med recidiverende eller refraktær eosinofil granulomatose med polyangiitis (EGPA) ) Modtagelse af standardbehandling (SoC) terapi
This study aims to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory EGPA receiving SoC therapy.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
-
La Plata, Argentina, B1900
- GSK Investigational Site
-
San Miguel de Tucumán, Argentina, T4000
- GSK Investigational Site
-
-
-
-
-
Santo André, Brasilien, 09060-870
- GSK Investigational Site
-
São Paulo, Brasilien, 4023900
- GSK Investigational Site
-
-
-
-
Ontario
-
Toronto, Ontario, Canada, M5T 3A9
- GSK Investigational Site
-
Toronto, Ontario, Canada, M5T 3L9
- GSK Investigational Site
-
-
-
-
-
Birmingham, Det Forenede Kongerige, B15 2GW
- GSK Investigational Site
-
London, Det Forenede Kongerige, SE1 7EH
- GSK Investigational Site
-
-
Cambridgeshire
-
Cambridge, Cambridgeshire, Det Forenede Kongerige, CB2 2QQ
- GSK Investigational Site
-
-
-
-
Colorado
-
Denver, Colorado, Forenede Stater, 80206
- GSK Investigational Site
-
-
Florida
-
Gainesville, Florida, Forenede Stater, 32610
- GSK Investigational Site
-
-
Minnesota
-
Rochester, Minnesota, Forenede Stater, 55905-0001
- GSK Investigational Site
-
-
New York
-
New York, New York, Forenede Stater, 10021-4823
- GSK Investigational Site
-
-
North Carolina
-
Charlotte, North Carolina, Forenede Stater, 28211
- GSK Investigational Site
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Forenede Stater, 15261
- GSK Investigational Site
-
-
-
-
-
Brest, Frankrig, 29609
- GSK Investigational Site
-
La Roche-sur-Yon, Frankrig, 85925
- GSK Investigational Site
-
Nantes, Frankrig, 44093
- GSK Investigational Site
-
Paris, Frankrig, 75014
- GSK Investigational Site
-
-
-
-
-
Groningen, Holland, 9713 GZ
- GSK Investigational Site
-
Leiden, Holland, 2333 ZA
- GSK Investigational Site
-
-
-
-
-
Ramat Gan, Israel, 52621
- GSK Investigational Site
-
-
-
-
-
Bari, Italien, 70124
- GSK Investigational Site
-
Brescia, Italien, 25123
- GSK Investigational Site
-
Florence, Italien, 50134
- GSK Investigational Site
-
Milan, Italien, 20132
- GSK Investigational Site
-
Milan, Italien, 20162
- GSK Investigational Site
-
Pavia, Italien, 27100
- GSK Investigational Site
-
Pisa, Italien, 56126
- GSK Investigational Site
-
Roma, Italien, 00128
- GSK Investigational Site
-
Torrette AN, Italien, 60126
- GSK Investigational Site
-
Treviso, Italien, 31100
- GSK Investigational Site
-
-
-
-
-
Kanagawa, Japan, 252-0392
- GSK Investigational Site
-
Kanagawa, Japan, 247-8533
- GSK Investigational Site
-
Saitama, Japan, 350-8550
- GSK Investigational Site
-
Tokyo, Japan, 181-8611
- GSK Investigational Site
-
Tokyo, Japan, 162-8666
- GSK Investigational Site
-
-
-
-
-
Beijing, Kina, 100005
- GSK Investigational Site
-
Guangzhou, Kina, 510163
- GSK Investigational Site
-
Hefei, Kina, 230001
- GSK Investigational Site
-
Nanjing, Kina, 210006
- GSK Investigational Site
-
Qingdao, Kina, 266071
- GSK Investigational Site
-
Shanghai, Kina, 200032
- GSK Investigational Site
-
Shenzhen, Kina, 518020
- GSK Investigational Site
-
Wenzhou, Kina, 325000
- GSK Investigational Site
-
-
-
-
-
Gdansk, Polen, 80-952
- GSK Investigational Site
-
Lodz, Polen, 90-153
- GSK Investigational Site
-
Warsaw, Polen, 01-138
- GSK Investigational Site
-
-
-
-
-
Lisbon, Portugal, 1649-035
- GSK Investigational Site
-
Porto, Portugal, 4099-001
- GSK Investigational Site
-
-
-
-
-
Barcelona, Spanien, 08036
- GSK Investigational Site
-
Barcelona, Spanien, 08035
- GSK Investigational Site
-
Granada, Spanien, 18014
- GSK Investigational Site
-
Pamplona, Spanien, 31008
- GSK Investigational Site
-
Zaragoza, Spanien, 50009
- GSK Investigational Site
-
-
-
-
-
Malmö, Sverige, SE-205 02
- GSK Investigational Site
-
-
-
-
-
Gwangju, Sydkorea, 61469
- GSK Investigational Site
-
Seoul, Sydkorea, 06351
- GSK Investigational Site
-
Seoul, Sydkorea, 06591
- GSK Investigational Site
-
Seoul, Sydkorea, 05505
- GSK Investigational Site
-
-
Seoul Teugbyeolsi
-
Seoul, Seoul Teugbyeolsi, Sydkorea, 3080
- GSK Investigational Site
-
-
-
-
-
Freiburg im Breisgau, Tyskland, 79106
- GSK Investigational Site
-
Minden, Tyskland, 32429
- GSK Investigational Site
-
-
-
-
-
Budapest, Ungarn, 1023
- GSK Investigational Site
-
-
-
-
Styria
-
Graz, Styria, Østrig, 8036
- GSK Investigational Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Participant (male or female) must be 18 years of age or older at the time of signing the informed consent.
- Participants who are >=40 kilogram at Screening Visit 1.
- Participants with a documented diagnosis of EGPA for at least 6 months based on the history or presence of: asthma plus eosinophilia defined as >1.0*10^9/Liter (L) and/or >10 percentage (%) of leucocytes plus at least 2 of the following additional features of EGPA: a biopsy showing histopathological evidence of eosinophilic vasculitis, or perivascular eosinophilic infiltration, or eosinophil-rich granulomatous inflammation, neuropathy, mono or poly (motor deficit or nerve conduction abnormality), pulmonary infiltrates, non-fixed, sino-nasal abnormality, cardiomyopathy (established by echocardiography or magnetic resonance imaging), glomerulonephritis (hematuria, red cell casts, proteinuria), alveolar hemorrhage (by bronchoalveolar lavage), palpable purpura, anti-neutrophil cytoplasmic antibodies positive Myeloperoxidase or Proteinase 3.
- History of relapsing OR refractory disease.
- Participants must be on a stable dose of oral prednisolone or prednisone of >=7.5 mg/day (but not >50 mg/day) or equivalent for at least 4 weeks prior to Baseline (Visit 2).
- If participants receiving immunosuppressive therapy (excluding cyclophosphamide) the dosage must be stable for the 4 weeks prior to Baseline (Visit 2) and during the study.
- A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies: Is a woman of non-childbearing potential (WONCBP) OR Is a woman of childbearing potential (WOCBP) and using a contraceptive method that is highly effective, with a failure rate of <1%.
- Capable of giving signed informed consent
Exclusion Criteria:
- Participants diagnosed with granulomatosis with polyangiitis; previously known as Wegener's granulomatosis or microscopic polyangiitis.
- Participants with organ-threatening EGPA as per EULAR criteria,
- Imminently life-threatening EGPA disease within 3 months prior to Screening (Visit 1).
- A current malignancy or previous history of cancer in remission for less than 12 months prior to Screening.
- Participants with alanine aminotransferase >2*upper limit of normal (ULN) or if participant is on background methotrexate or azathioprine >3*ULN, aspartate aminotransferase >2*ULN or if participant is on background methotrexate or azathioprine >3*ULN, alkaline phosphatase >=2.0*ULN, total bilirubin >1.5*ULN (isolated bilirubin >1.5*ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%), Cirrhosis or current unstable liver or biliary disease per investigator assessment.
- Participants who have severe or clinically significant cardiovascular disease uncontrolled with standard treatment.
- Participants who have known, pre-existing, clinically significant system abnormalities that are not associated with EGPA and are uncontrolled with standard treatment.
- Clinically significant abnormality in the hematological, biochemical or urinalysis screen at Visit 1.
- Chronic or ongoing active infectious disease requiring systemic treatment.
- Participants with a known, pre-existing parasitic infestation within 6 months prior to Screening Visit 1.
- A known immunodeficiency (e.g., human immunodeficiency virus [HIV]).
- Participants that, according to the investigator's medical judgment, are likely to have active coronavirus disease 2019 (COVID-19) infection. Participants with known COVID-19 positive contacts within the past 14 days must be excluded for at least 14 days following the exposure during which the participant must remain symptom-free.
- Participants with a known allergy or intolerance to a monoclonal antibody or biologic therapy or any of the excipients of the investigational products.
- Participants who have a previous documented failure with anti-Interleukin-5 /Interleukin-5 receptor therapy (e.g., mepolizumab, reslizumab, benralizumab). Participants who have received monoclonal antibodies (mAb) and who have not undergone the required washout periods, prior to Visit 1.
- Participants receiving any of the following: Oral corticosteroids: Participant requires an oral corticosteroid dose of >50 mg/day prednisolone/prednisone in the 4-week period prior to Baseline (Visit 2), Intravenous (IV), intramuscular or subcutaneous (SC) corticosteroids in the 4-week period prior to Baseline (Visit 2), Omalizumab within 130 days prior to Screening (Visit 1), Cyclophosphamide (CYC): oral CYC within 4 weeks prior to Baseline (Visit 2) and IV CYC within 3 weeks prior to Baseline (Visit 2), if their total white blood cells is >=4*10^9/L (measured using the local laboratory if necessary), Rituximab within 12 months prior to Screening (Visit 1); in addition, the Participant must have shown recovery of peripheral B-cell count to within the normal range, Tezepelumab and Dupilumab with a washout period of 5 half-lives prior to Screening Visit 1, IV or SC immunoglobulin within 6 months prior to Screening (Visit 1); For China and Japan only within 12 weeks prior to Screening (Visit 1), Interferon-alpha within 6 months prior to Screening Visit 1, Anti-tumor necrosis factor therapy within 12 weeks prior to Screening Visit 1, Anti-CD52 (alemtuzumab) within 6 months prior to Screening Visit 1.
- Participants with QT interval corrected for heart rate according to Fridericia's formula (QTcF) >=450 milliseconds (msec) or QTcF >=480 msec for participants with Bundle Branch Block in the 12-lead ECG central over-read from at Screening Visit 1.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Deltagere, der fik depemokimab+placebo-matchende mepolizumab
|
Depemokimab will be administered Placebo matching to mepolizumab will be administered. |
|
Aktiv komparator: Deltagere, der fik mepolizumab+placebo-matchende depemokimab
|
Mepolizumab will be administered Placebo matching to depemokimab will be administered. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of participants with remission (Birmingham Vasculitis Activity Score [BVAS] =0 and a dose of oral corticosteroid [OCS] less than or equal to [<=] 4 milligram [mg] per day)
Tidsramme: Up to Week 52
|
Participants must be in remission at both Weeks 36 and 52. |
Up to Week 52
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Antal deltagere, der opnår remission ved at bruge definitionen af European League against Rheumatism (EULAR) (BVAS = 0 og OCS <=7,5 mg/dag) i uge 36 og 52
Tidsramme: I uge 36 og 52
|
I uge 36 og 52
|
|
|
Antal deltagere med remission (BVAS=0 og OCS <=7,5 mg/dag) inden for de første 24 uger med fortsat remission indtil uge 52
Tidsramme: Op til uge 52
|
Op til uge 52
|
|
|
Antal deltagere, der opnår remission (BVAS = 0 og OCS ≤ 4 mg/dag) inden for de første 24 uger med vedvarende remission indtil uge 52
Tidsramme: Op til uge 52
|
Op til uge 52
|
|
|
Number of participants in each category of accrued duration of remission
Tidsramme: Up to Week 52
|
Total accrued duration of remission is the accrued number of weeks where BVAS = 0 plus OCS dose <= 4 mg/day over the 52-week intervention period. The accrued duration was categorized into zero, >0 to <12 weeks, 12 to <24 weeks, 24 to <36 weeks or more than or equal to (>=) 36 weeks. |
Up to Week 52
|
|
Number of participants with total accrued duration of remission
Tidsramme: Up to Week 52
|
Total accrued duration of remission is the accrued number of weeks where BVAS = 0 plus OCS dose <= 4 mg/day over the 52-week intervention period. |
Up to Week 52
|
|
Time to first EGPA relapse
Tidsramme: Up to Week 52
|
The time to first EGPA relapse will be calculated from the date of first dose of study intervention and start date of the EGPA relapse. |
Up to Week 52
|
|
Number of participants receiving in each category of mean OCS dose during the last 4 weeks of study treatment period (Weeks 49 to 52)
Tidsramme: Weeks 49 to 52
|
Number of participants receiving the mean OCS dose (categorized as 0, >0 to <=4, >4 to <=7.5 or >7.5 mg/day) will be assessed during the last 4 weeks of the study treatment period (Weeks 49 to 52). |
Weeks 49 to 52
|
|
Number of participants in each category of accrued duration of remission according to the EULAR definition of remission (BVAS = 0 plus OCS <=7.5 mg/day) over 52-week intervention period
Tidsramme: Up to Week 52
|
Total accrued duration of remission according to the EULAR definition of remission is the accrued number of weeks where BVAS = 0 plus OCS dose <=7.5 mg/day over the 52 week intervention period categorized as zero weeks; >0 to <12 weeks; 12 to <24 weeks; 24 to <36 weeks or >= 36 weeks. |
Up to Week 52
|
|
Number of participants with total accrued duration of remission according to the EULAR definition of remission
Tidsramme: Up to Week 52
|
Total accrued duration of remission according to the EULAR definition of remission is the accrued number of weeks where BVAS=0 plus OCS <=7.5 mg/day over the 52-week intervention period. |
Up to Week 52
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: GSK Clinical Trials, GlaxoSmithKline
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Karsygdomme
- Hjerte-kar-sygdomme
- Autoimmune sygdomme
- Sygdomme i immunsystemet
- Hudsygdomme
- Lymfesygdomme
- Lymfoproliferative lidelser
- Hudsygdomme, vaskulære
- Vaskulitis
- Anti-neutrofil cytoplasmatisk antistof-associeret vaskulitis
- Granulom
- Systemisk vaskulitis
- Hud- og bindevævssygdomme
- Hemiske og lymfatiske sygdomme
- Churg-Strauss syndrom
- Mepolizumab
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 217102
- 2023-510019-20-00 (Anden identifikator: EU CT Number)
- 2021-005726-15 (Registry Identifier: EudraCT (EU))
- 2023-510019-20-00 (Registry Identifier: CTIS (EU))
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
IPD for this study will be made available via the Clinical Study Data Request site.
IPD-delingstidsramme
IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
IPD-delingsadgangskriterier
Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .